Monte Rosa Therapeutic (GLUE) Q4 2024 earnings summary

Executive summary

• Reported Q4 and full year 2024 results, highlighting clinical and preclinical progress in immunology, inflammation, and oncology pipelines, with a focus on molecular glue degraders and strategic prioritization of castration-resistant prostate cancer (CRPC) for MRT-2359.

• Advanced MRT-6160 (VAV1 program) with positive Phase 1 data (>90% VAV1 degradation, robust T/B cell inhibition, favorable safety), supporting Phase 2 development and a global partnership with Novartis.

• Progressed NEK7 program (MRT-8102) toward IND filing, with preclinical data supporting safety and efficacy in inflammatory diseases; IND submission expected H1 2025.

• MRT-2359 showed early efficacy in CRPC (1 PR, 2 SD in first 3 evaluable patients), with strategic focus shifting away from lung and neuroendocrine tumors due to low biomarker positivity.

• CCNE1 and CDK2 programs demonstrated strong preclinical efficacy in cancer models, with IND submissions targeted for 2026.

Financial highlights

• Received $150M upfront from Novartis for global license of MRT-6160, with potential for up to $2.1B in milestones and US profit/loss share plus ex-US royalties.

• Q4 2024 collaboration revenue: $60.6M; full year 2024: $75.6M, reflecting new Novartis and Roche agreements.

• Cash, equivalents, and marketable securities at Dec 31, 2024: $377M, up from $247.1M at Sep 30, 2024; cash runway anticipated into 2028.

• Q4 2024 net income: $13.4M (vs. $33.3M net loss in Q4 2023); full year 2024 net loss: $72.7M (improved from $135.4M loss in 2023).

Outlook and guidance

• Phase 2 initiation for MRT-6160 planned; IND submission for NEK7 (MRT-8102) in H1 2025; additional CRPC and HR+ breast cancer data for MRT-2359 expected in H2 2025.

• IND submissions for CCNE1/CDK2 and CNS-optimized NEK7 programs targeted for 2026.